论文部分内容阅读
最初记载门脉高压症这个术语的是Mclnd-ol(1928),确立其基本概念的是Laousselat 和Thompson 等人。一旦出现门脉高压,不论其原因为何,迟早要出现脾肿大、脾功能亢进(全血细胞减少)、腹水,建立侧支循环,形成食道静脉曲张以及因其破裂而发生出血等继发症状,病理改变极其复杂多样,给患者预后带来重大影响。因此,门脉高压并非指单一疾病,而是指门脉压增高和包括由它的结果产生的继发病理改变在内的症状的总称。门脉高压症是一种门脉血循异常状态,最终降低门脉压是临床上的重要课题。最近不论内科或外科均积极开展多种多样新疗法,取得可观的成果。本文仅就其保守疗法与存在问题加以叙述。
The original term for portal hypertension was Mclnd-ol (1928), and Laousselat and Thompson et al. Established the basic concepts. In the event of portal hypertension, regardless of the reason why, sooner or later to appear splenomegaly, hypersplenism (pancytopenia), ascites, the establishment of collateral circulation, the formation of esophageal varices and bleeding due to rupture and other secondary symptoms, Pathological changes are extremely complex and diverse, bringing a significant impact on the prognosis of patients. Thus, portal hypertension does not refer to a single disease, but refers to the general term for increased portal pressure and symptoms including secondary pathological changes resulting from its results. Portal hypertension is a portal vein abnormalities, the final reduction of portal pressure is an important clinical issue. In recent years, both internal medicine and surgery are active in a wide range of new treatments, and achieved impressive results. This article describes only its conservative therapy and its existence.